Advisers squabble over Mylan's desire for Perrigo; Benitec downsizes its IPO plans;

@FierceBiotech: FierceBiotech Radio on Amarin's First Amendment crusade, Martin Shkreli's Twitter, and Kim Kardashian's Instagram. Listen/Subscribe | Follow @FierceBiotech

@JohnCFierce: California cutbacks: Boston Sci to close two facilities, Abbott cuts 160+ employees. FierceMedicalDevices article | Follow @JohnCFierce

@DamianFierce: ICYMI: A wonderfully stern FDA official parses Kim Kardashian's Instagram. Letter | Follow @DamianFierce

> Proxy advisers are arguing over whether Mylan ($MYL) shareholders should support the company's efforts to acquire Perrigo ($PRGO) for around $200 per share. News

> Benitec Biopharma has scaled back its IPO ambitions, planning to raise just $15 million, a 41% reduction on its earlier plans. Story

> Water Street won FDA approval for the antibiotic Cefazolin, developed in collaboration with Baxter ($BAX). More

Medical Device News

@FierceMedDev: Roche shells out up to $425M for superbug testing outfit. FierceDiagnostics news | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Google joins forces with Dexcom for miniaturized glucose monitor. Article | Follow @VarunSaxena2

@EmilyWFierce: NICE plots takeover of England's Cancer Drugs Fund. FiercePharma article | Follow @EmilyWFierce

> NOWDiagnostics gets FDA blessing for one-step pregnancy test. News

> Roche deploying smartphone app to monitor patients during clinical trial of its Parkinson's med. Report

> NIH study sees little benefit to added fetal ECG monitoring during birth. Story

Pharma News

@FiercePharma: China FDA issues software guidelines on medical devices effective this month. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Sun U.S. sales gut-kicked by supply constraints as it works on FDA concerns at Halol plant. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Biogen touts new Eloctate data as next-gen hemophilia rivals near the scene. FiercePharmaMarketing article | Follow @CarlyHFierce

> Novo says new U.S. plant may be best bet to offset the FX bite. More

> Shire raise its $30B Baxalta bid? It's going to need some details first. Article

> Takeda Actos settlement seems shaky as plaintiffs give it the sniff test. Story

> NICE plots takeover of England's Cancer Drugs Fund. Report

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.